Real-World data reveals how dapagliflozin works for kidney disease

NCT ID NCT07450820

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study analyzed electronic health records of nearly 13,000 adults with chronic kidney disease in Spain to see how the drug dapagliflozin is used in everyday practice. Researchers looked at patient characteristics, lab results, and healthcare costs over 39 months. The goal was to understand treatment patterns and outcomes, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If successful, this study could provide real-world evidence on how dapagliflozin is used and its effectiveness in managing chronic kidney disease in routine clinical practice.
What could go wrong: As an observational study, it cannot prove cause and effect. Results may be influenced by factors like patient selection or data quality, and may not apply to all CKD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Research Site

Madrid, 28002, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.